Otsuka invests $88M into digital meds deal with Proteus; Celgene amps up research pact with Evotec

→ Japan’s Otsuka has handed over an $88 million payment to Proteus Digital Health for a collaboration on the development of digital meds. They will be working on the Abilify Mycite System and “joint development of an expanded portfolio of digital medicines consisting of other therapies such as atypical antipsychotics used in the treatment of serious mental illness integrated with Proteus sensors.”

Celgene $CELG is still cautiously exploring neurosciences. Expanding a discovery collaboration with Evotec that started in late 2016, Celgene is handing over another $6 million for additional cell lines on Evotec’s human induced pluripotent stem cell (iPSC) tech platform, opening up “additional opportunities for further research into disease-modifying treatments” for neurodegeneration.

→ Boston startup Jnana Therapeutics has found a research partner in San Diego, combining their knowledge of solute carrier, or SLC, transporters with Neurocrine’s R&D expertise to search for new small molecule drugs for central nervous system disorders. Neurocrine $NBIX is paying an undisclosed upfront and footing the bill for the joint discovery work, after which it will take over any work on lead optimization and development.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->